ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder | Small Molecules | News Channels - PipelineReview.com

Submitted by Anonymous (not verified) on Thu, 04/25/2019 - 16:44

ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder | Small Molecules | News Channels  PipelineReview.comACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder.